PTPRO and breast cancer: Evidence indicates that PTPRO can be downregulated via methylation in some forms of tumors, such as breast cancer, hepatocellular carcinoma, lung cancer, chronic lymphocytic leukemia, and esophageal carcinoma 13-18.